Urinary Incontinence, Urge
2
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
AbbVieNORTH CHICAGO, IL
1 programBladder Antimuscarinic Medication and Accidental Bowel LeakageN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Human BioSciencesInterStim® device
ColoplastINTIBIA Therapeutic
AbbVieBladder Antimuscarinic Medication and Accidental Bowel Leakage
Clinical Trials (3)
Total enrollment: 626 patients across 3 trials
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Start: Feb 2012Est. completion: Jul 2016386 patients
Phase 3Completed
INTIBIA Pivotal Study
Start: Mar 2022Est. completion: Jun 2026208 patients
N/AActive Not Recruiting
Bladder Antimuscarinic Medication and Accidental Bowel Leakage
Start: May 2018Est. completion: Jan 201932 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.